Spark Therapeutics, Inc. (NASDAQ:ONCE)

CAPS Rating: 4 out of 5

Caps

How do you think ONCE will perform against the market?

Add Stock to CAPS Watchlist

All Players

44 Outperform
3 Underperform
 

All-Star Players

16 Outperform
1 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top ONCE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

pchop12316 (93.14)
Submitted February 27, 2015

anticipated fast ride upward

TSIF (99.97)
Submitted October 05, 2015

WARNING: BIOPHARMS on "news", (testing results, approvals) can overshoot, drop and climb much higher as shorts / speculators jockey with day traders to open and close positions... my thumbing is based on past patterns and the only rule I have about… More

ONCE VS S&P 500 (SPY)

ONCE Summary

Recent Community Commentary

Read the most recent pitches from players about ONCE.

Recs

0
Member Avatar clangmead (59.39) Submitted: 8/3/2017 10:18:59 AM : Outperform Start Price: $77.04 ONCE Score: -1.07

ML

Recs

0
Member Avatar zzlangerhans (99.80) Submitted: 10/16/2015 2:18:28 PM : Outperform Start Price: $53.15 ONCE Score: +18.54

I really don't have time to get into the nuts and bolts of Spark's recent topline data release from the phase III trial of SPK-RPE65. The trial met the primary endpoint of mobility testing but was mixed on secondary endpoints, notably failing to improve visual acuity on an eye chart. The benefits seem to last for a few years at least. The data is almost certainly sufficient to get a BLA accepted by the FDA, and probably approved. The main question is whether the amount of benefit is sufficient to justify what almost certainly will be a price tag in the high six figures, and whether payors will foot the bill. Just a few months ago, Spark's data release would have doubled the share price on that day and the stock would likely have kept floating upward into 2016. In the current climate of biotech sector weakness and new regulatory fears, investors are uncertain and Spark stock has been shaky.

Portefeuille and I have taken our position on the biotech sector and gene therapy in particular. We think the current iteration of gene therapeutics is for real, and that it is part of the reason we're in a biotech boom and not a bubble. That's why we continue to take on water on Bluebird and UniQure as those stocks fail to hold recent gains despite an absence of true negative catalysts. If we're wrong, we're wrong and we'll take our lumps. But for now we'll stick to our guns. 260 Spark shares in zzporte with cost basis 50.61.

Recs

0
Member Avatar sullyz0r (45.38) Submitted: 5/28/2015 11:24:30 AM : Outperform Start Price: $68.57 ONCE Score: -5.32

Closing out bluebird and adding spark to replace. Bluebird's getting a bit crazy for me here, and sold in real life. Probably will miss out on thousands, but it's too early and frothy. ONCE isn't much less frothy, but it's all relative, right?

Leaderboard

Find the members with the highest scoring picks in ONCE.

Score Leader

paullng

paullng (< 20) Score: +200.62

The Score Leader is the player with the highest score across all their picks in ONCE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
paullng < 20 2/10/2016 Outperform 3Y $22.61 +230.83% +30.20% +200.62 0 Comment
portefeuille 98.64 2/10/2016 Outperform 5Y $23.30 +221.03% +29.28% +191.75 0 Comment
dollarsandcents1 < 20 4/6/2016 Outperform 5Y $32.29 +131.65% +18.81% +112.84 0 Comment
jeepdrew222 76.83 5/16/2016 Outperform 5Y $33.77 +121.50% +18.42% +103.08 0 Comment
jettyjett < 20 1/4/2016 Outperform 5Y $41.33 +80.98% +21.36% +59.62 0 Comment
2015investor < 20 12/21/2015 Outperform 3M $44.56 +67.88% +21.18% +46.71 0 Comment
gypsystem < 20 8/31/2015 Outperform 5Y $45.52 +64.32% +22.51% +41.81 0 Comment
ababrmon 88.18 8/14/2015 Outperform 1Y $48.20 +55.18% +16.24% +38.94 0 Comment
drschitt 40.43 12/15/2015 Outperform 5Y $48.18 +55.27% +18.05% +37.22 0 Comment
superstar2 99.36 7/6/2016 Outperform 5Y $51.53 +45.16% +15.83% +29.33 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.81 9/8/2016 Outperform 3W $59.90 +24.87% +11.08% +13.80 0 Comment
TrackJimCramer 84.81 9/28/2015 Underperform 3W $42.54 +40.81% +16.28% -24.52 9/8/2016 @ $59.90 0 Comment
TrackJimCramer 84.81 7/22/2015 Outperform 3W $67.15 -36.65% -11.07% -25.58 9/28/2015 @ $42.54 0 Comment

Featured Broker Partners